Dear [Name],

Thank you for the constructive discussion held on 14 May on the AstraZeneca plans for the development, production and introduction of a vaccine for prophylaxis against COVID-19.

As discussed, please find attached a questionnaire addressed to your company. We would be grateful if you could reply to the questions it contains by Friday 22 May close of business.

Insofar as the information provided by you contains business secrets, your information will obviously be kept confidential (see Article 339 TFEU).

Yours sincerely,

(e-signed)

Céline GAUER

Enclosure: Questionnaire